BIIB Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of 19% compared to Biogen, Inc.'s net margin of 20.1%. Biogen, Inc.'s return on equity of 9.36% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.

Biogen, Inc. has a consensus price target of $192.31, signalling upside risk potential of 10.45%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $485.76 which suggests that it could grow by 36.93%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Biogen, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Biogen, Inc..

Biogen, Inc. has a beta of 0.127, which suggesting that the stock is 87.301% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.539%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Biogen, Inc. quarterly revenues are $2.5B, which are larger than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Biogen, Inc.'s net income of $466.5M is higher than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Biogen, Inc.'s price-to-earnings ratio is 15.88x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,475.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 2.63x versus 14.55x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of 19% compared to Biogen, Inc.'s net margin of -259.95%. Biogen, Inc.'s return on equity of 9.36% beat Insmed, Inc.'s return on equity of -193.23%.

Biogen, Inc. has a consensus price target of $192.31, signalling upside risk potential of 10.45%. On the other hand Insmed, Inc. has an analysts' consensus of $214.00 which suggests that it could grow by 31.58%. Given that Insmed, Inc. has higher upside potential than Biogen, Inc., analysts believe Insmed, Inc. is more attractive than Biogen, Inc..

Biogen, Inc. has a beta of 0.127, which suggesting that the stock is 87.301% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.085, suggesting its more volatile than the S&P 500 by 8.523%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Biogen, Inc. quarterly revenues are $2.5B, which are larger than Insmed, Inc. quarterly revenues of $142.3M. Biogen, Inc.'s net income of $466.5M is higher than Insmed, Inc.'s net income of -$370M. Notably, Biogen, Inc.'s price-to-earnings ratio is 15.88x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 2.63x versus 69.21x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 19% compared to Biogen, Inc.'s net margin of 31.72%. Biogen, Inc.'s return on equity of 9.36% beat Eli Lilly & Co.'s return on equity of 106.26%.

Biogen, Inc. has a consensus price target of $192.31, signalling upside risk potential of 10.45%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,123.04 which suggests that it could grow by 8.04%. Given that Biogen, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Biogen, Inc. is more attractive than Eli Lilly & Co..

Biogen, Inc. has a beta of 0.127, which suggesting that the stock is 87.301% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Biogen, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen, Inc. quarterly revenues are $2.5B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Biogen, Inc.'s net income of $466.5M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Biogen, Inc.'s price-to-earnings ratio is 15.88x while Eli Lilly & Co.'s PE ratio is 51.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 2.63x versus 15.95x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Stoke Therapeutics, Inc. has a net margin of 19% compared to Biogen, Inc.'s net margin of -360.68%. Biogen, Inc.'s return on equity of 9.36% beat Stoke Therapeutics, Inc.'s return on equity of 13.95%.

Biogen, Inc. has a consensus price target of $192.31, signalling upside risk potential of 10.45%. On the other hand Stoke Therapeutics, Inc. has an analysts' consensus of $37.13 which suggests that it could grow by 26.92%. Given that Stoke Therapeutics, Inc. has higher upside potential than Biogen, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Biogen, Inc..

Biogen, Inc. has a beta of 0.127, which suggesting that the stock is 87.301% less volatile than S&P 500. In comparison Stoke Therapeutics, Inc. has a beta of 1.102, suggesting its more volatile than the S&P 500 by 10.227%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen, Inc. pays -- of its earnings as a dividend. Stoke Therapeutics, Inc. pays out -- of its earnings as a dividend.

Biogen, Inc. quarterly revenues are $2.5B, which are larger than Stoke Therapeutics, Inc. quarterly revenues of $10.6M. Biogen, Inc.'s net income of $466.5M is higher than Stoke Therapeutics, Inc.'s net income of -$38.3M. Notably, Biogen, Inc.'s price-to-earnings ratio is 15.88x while Stoke Therapeutics, Inc.'s PE ratio is 44.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 2.63x versus 8.30x for Stoke Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.